Management Team.

Lynne Robertson, MS, PhD

Chief Scientific Officer

Lynne has over 35 years of experience in the pharmaceutical industry and life sciences, specializing in the interpretation and application of regulatory requirements for timely, efficient, and cost-effective health care product development.

As Chief Scientific Officer for Temple Therapeutics, Lynne oversaw development of the company’s postsurgical fibrosis asset through phase 2a. She was also instrumental in bringing in the company’s early development asset for the treatment of benign and malignant conditions of dysregulated cellular growth, including ovarian cancer and endometriosis.  

An expert in the development of drugs, devices, and biologics from concept to commercial launch, Lynne has been Principal Consultant and Co-founder since 2004 at Gwen Ryan Solutions, LLC, a pharmaceutical development consulting firm. Prior to joining Temple Therapeutics, she served as Chief Operations Officer and Executive Vice President of Regulatory and Development at AdeTherapeutics, Inc. She has also served as Chief Scientific Officer for Nostrum Technologies. Prior to that, she served as Director of Regulatory Product Development at Quintiles Consulting, Inc., and Director of Project Management at Kos Pharmaceuticals. Lynne has also held senior management, regulatory (consultant), and technical positions at leading pharma companies, including Biogen, Johnson and Johnson, Shire, Mylan, Schering-Plough, Acorda, and Wyeth Ayerst. Lynne received her PhD in Pharmacology and MS in Biochemistry from the University of Vermont.